Posted on Thursday 30 June 2022 by Luke Hamm | Chief Executive Officer
The UK Digital Strategy policy paper was published on 13 June 2022. It reconfirms the government’s intent to make the UK the best place in the world to start and grow a technology business and it seeks to outline this vision and the actions required to deliver it.
Posted on Wednesday 22 June 2022 by Tanya Rahman | Junior Intellectual Property Analyst
For too long, and for too many, R&D tax relief has been a tick box exercise of tax planning. However, HMRC has drawn a line in the sand when it comes to abuse of the R&D tax relief scheme. This change of tack is well overdue and should protect the integrity of the schemes.
Posted on Wednesday 9 February 2022 by Luke Hamm | Chief Executive Officer
There are currently a lot of players in the exceptionally crowded space of R&D tax credits. As a consequence, there are probably a lot of conflicting messages. These range from “get hundreds of thousands of pounds in 30 minutes with zero risk” to “the wolf is at the door so proceed with serious caution”. As always the truth is somewhere between those two positions.
> Read more
Posted on Thursday 2 December 2021 by Luke Hamm | Chief Executive Officer
Following on from that consultation reforms that were announced in the Autumn Budget 2021, the government:
Today we got more of the detail of these reforms and understood more of the next steps.
> Read more
Posted on Friday 1 October 2021 by Luke Hamm | Chief Executive Officer
The latest statistics showing the value of R&D tax relief and Patent Box were published by HMRC yesterday. What does an initial look at this year’s numbers tell us?
> Read more
Posted on Thursday 19 November 2020 by Luke Hamm | Chief Executive Officer
We know that a lot of competitors have a “calculator” on their website or examples of R&D claims. We’ve never felt that this was necessary, not because it’s difficult or mysterious – but because it asks the wrong question and therefore gives you the wrong answer.
> Read more
Posted on Wednesday 16 September 2020 by Vanessa Cooper | Group Technical Tax Manager
We have had some clarification from HMRC on how companies furloughing staff deal with claims under the SME R&D tax relief or Research and Development Expenditure Credit (RDEC) schemes. It’s important to realise that the rules are different under each of these schemes. But also that small and medium enterprises can claim under the RDEC scheme.
> Read more
Posted on Friday 29 May 2020 by Vanessa Cooper | Group Technical Tax Manager
GovGrant sits on the Research & Development Consultative Committee (RDCC) to represent UK’s business when it comes to the operational delivery of the R&D tax relief schemes. This is an HMRC-sponsored forum, and as members we receive regular updates as HMRC advice evolves and develops. We are currently in an unprecedented period of change, with the introduction of new and vital measures to support business British business.> Read more
Posted on Tuesday 15 October 2019 by Luke Hamm | Chief Executive Officer
In their latest podcast, Accountancy Age spoke to GovGrant’s CEO, Luke Hamm, about the need for the R&D tax credit programme to be kickstarted in the UK in order to drive much-needed innovation. In this entertaining podcast, we cover why the government must do more, how businesses of all sizes are missing out, the regional problem and why the big four need to take some of the blame for the issue.
Posted on Friday 3 May 2019 by Luke Hamm | Chief Executive Officer
The UK’s biopharma and medtech sector is a world class sector with potential for stellar growth, according to Luke Hamm, CEO of GovGrant, which helps companies in the sector obtain commercialise their innovations, including R&D tax credits. Commenting after the publication of the government’s Office For Life Science’s (OLS) statistical survey of biotech and medtech in the UK, Luke said: “The report underlines the vital importance of this sector to the UK economy, with a quarter of a million employees, turnover of nearly £75bn and over 6,000 businesses across the four key areas.” [biopharma, biopharma service and supply, med tech core and med tech supplier businesses.]
Posted on Monday 18 February 2019 by Luke Hamm | Chief Executive Officer
Australian government proposals to restrict tax incentives for R&D and innovation have been delayed following an outcry from business and research groups. The proposals, intended to save £1.2bn capped cash refunds for research activities at $4m, introduced a new ‘intensity test’ for larger companies to favour higher, more intensive R&D investment, and significantly increased compliance and enforcement measures, according to a report in the Guardian newspaper.
UK Digital Strategy – full on intent but lighter on new policy
Get ahead with your R&D tax relief
Response to R&D Tax Reliefs Consultation – further information 2022
What’s changing in the R&D tax relief market?
How to select the right R&D advisor for your business?
